未登录

W

Wenzhi Tian

fudan university

H指数:19

被引数:1,519

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapy

IMM2510，一种新型抗PD-L1/VEGF双特异性抗体用于癌症免疫治疗

Antibody Therapeutics

IF4.5

2026-01-010

PRE

Ferroptosis in thyroid cancer: mechanisms, current status, and treatment

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-230

OAAI

Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

JOURNAL OF HEMATOLOGY & ONCOLOGY

IF40.4

2024-12-180

OAAI

Development of bioassay platforms for biopharmaceuticals using Jurkat-CAR cells by AICD

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

IF3.1

2024-12-010

OAAI

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-09-240

OAAI

Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

FRONTIERS IN ONCOLOGY

IF3.3

2024-07-057

OAAI

Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38

结合CD38抗体和CD47阻断是治疗表达CD38的血液系统恶性肿瘤的有希望的策略

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-06-251

OAAI

Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma

CANCER RESEARCH

IF16.6

2024-04-050

PRE

Preclinical development of a bispecific antibody-trap selectively targeting CD38 and CD47 for treating hematologic malignancies

CANCER RESEARCH

IF16.6

2024-04-050

PRE

IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study

CANCER RESEARCH

IF16.6

2024-04-050

PRE

The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling

FRONTIERS IN ONCOLOGY

IF3.3

2023-10-025

OAAI

Preclinical development of a monoclonal antibody targeting CD24 as cancer immunotherapy

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Preclinical development of a monoclonal antibody targeting CD70 as cancer immunotherapy

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2520, targeting both PD-L1 and CD47 as cancer immunotherapy

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2902, targeting both HER2 and CD47 as cancer immunotherapy

CANCER RESEARCH

IF16.6

2023-04-043

PRE

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcγR engagement by simultaneously binding to CD47 and CD20 of B cells

IF13.4

2022-12-2720

OAAI

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the don't eat me signal and activating the eat me signal

JOURNAL OF HEMATOLOGY & ONCOLOGY

IF40.4

2022-11-1623

OAAI

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)

IF4.6

2022-08-3013

OAAI

A SIRPαFc Fusion Protein Conjugated With the Collagen-Binding Domain for Targeted Immunotherapy of Non-Small Cell Lung Cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-03-2915

OAAI

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo (vol 11, 5774, 2021)

SCIENTIFIC REPORTS

IF3.9

2022-03-281

OAAI